Targeting pan-essential pathways in cancer with cytotoxic chemotherapy: challenges and opportunities.

Autor: Rudd SG; Science For Life Laboratory, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden. sean.rudd@scilifelab.se.
Jazyk: angličtina
Zdroj: Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2023 Oct; Vol. 92 (4), pp. 241-251. Date of Electronic Publication: 2023 Jul 15.
DOI: 10.1007/s00280-023-04562-3
Abstrakt: Cytotoxic chemotherapy remains a key modality in cancer treatment. These therapies, successfully used for decades, continue to transform the lives of cancer patients daily. With the high attrition rate of current oncology drug development, combined with the knowledge that most new therapies do not displace standard-of-care treatments and that many healthcare systems cannot afford these new therapies; cytotoxic chemotherapies will remain an important component of cancer therapy for many years to come. The clinical value of these therapies is often under-appreciated within the pre-clinical cancer research community, where this diverse class of agents are often grouped together as non-specific cellular poisons killing tumor cells based solely upon proliferation rate; however, this is inaccurate. This review article seeks to reaffirm the importance of focusing research efforts upon improving our basic understanding of how these drugs work, discussing their ability to target pan-essential pathways in cancer cells, the relationship of this to the chemotherapeutic window, and highlighting basic science approaches that can be employed towards refining their use.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: